Bayer Management Changes May Suggest Deepening Xarelto Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Delayed appointments of new CEO and CFO may strengthen German pharma's M&A capabilities.
You may also be interested in...
Boehringer Ingelheim: Privacy Has its Virtues
Boehringer Ingelheim has beaten market growth for the past nine years and may continue to outperform rivals. Part of the secret: its private status affords the group a long-term outlook that's far trickier for its public peers to embrace.
Boehringer Ingelheim: Privacy Has its Virtues
Boehringer Ingelheim has beaten market growth for the past nine years and may continue to outperform rivals. Part of the secret: its private status affords the group a long-term outlook that's far trickier for its public peers to embrace.
FDA Warning Letter Asks Bayer To Fix Manufacturing Practices In German Facility
FDA says Bayer's facility in Bergkamen, Germany, is still not up to par with good manufacturing practices in the U.S.